---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-077876"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2023-03-23T23:59:59+00:00"
generated_at: "2026-06-17T19:13:57.018586+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Invivyd FY2022 net loss $241.3M; advancing VYD222 mAb into clinic

## Summary
- Cash, cash equivalents and marketable securities $372M as of Dec 31, 2022, expected to fund operations into H2 2024.
- Net loss $241.3M ($2.23 per share) for FY2022 vs $226.8M ($5.32 per share) in FY2021.
- R&D expenses $183.6M, down slightly from $190.4M in FY2021.
- Advancing VYD222 into Phase 1 clinical trial in Q1 2023; in vitro data shows neutralizing activity against XBB.1.5.
- Appointed Jeremy Gowler as COO and promoted Pete Schmidt to CMO.

## SEC filing metadata
- accession: 0001193125-23-077876
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2023-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000119312523077876/0001193125-23-077876-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000119312523077876/d450944d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-077876
- JSON: https://secwatch.observer/filing/0001193125-23-077876.json
- Plain text: https://secwatch.observer/filing/0001193125-23-077876.txt

## Key facts
- Earnings Releases
  Invivyd, Inc. reported the year ended December 31, 2022 results: net income $241.3 million.
  - Period: the year ended December 31, 2022
  - Net income: $241.3 million
  - Result: reported results
  source text: Net loss was $241.3 million for the year ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1832038/000119312523077876/0001193125-23-077876-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.